These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22530244)

  • 41. Modifying disease in cystic fibrosis: current and future therapies on the horizon.
    Ong T; Ramsey BW
    Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
    Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
    Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Orphan cystic fibrosis drugs find sister diseases.
    Dolgin E
    Nat Med; 2011 Apr; 17(4):397. PubMed ID: 21475214
    [No Abstract]   [Full Text] [Related]  

  • 44. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.
    Chassagnon G; Hubert D; Fajac I; Burgel PR; Revel MP;
    Eur Respir J; 2016 Jul; 48(1):249-52. PubMed ID: 27230445
    [No Abstract]   [Full Text] [Related]  

  • 49. Breathing easier with combinations.
    Azvolinsky A
    Nat Biotechnol; 2015 Nov; 33(11):1128-30. PubMed ID: 26544137
    [No Abstract]   [Full Text] [Related]  

  • 50. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
    Elborn JS; Ramsey B; Wainwright C; Boyle M
    Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
    [No Abstract]   [Full Text] [Related]  

  • 51. [Cystic fibrosis: new treatments targeting the CFTR protein].
    Fajac I; Sermet-Gaudelus I
    Rev Mal Respir; 2013 Apr; 30(4):255-61. PubMed ID: 23664284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hot off the breath: 'I've a cost for'--the 64 million dollar question.
    Bush A; Simmonds NJ
    Thorax; 2012 May; 67(5):382-4. PubMed ID: 22407889
    [No Abstract]   [Full Text] [Related]  

  • 54. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation.
    Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ
    Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
    Dryden C; Wilkinson J; Young D; Brooker RJ;
    Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.
    Durmowicz AG; Lim R; Rogers H; Rosebraugh CJ; Chowdhury BA
    Ann Am Thorac Soc; 2018 Jan; 15(1):1-2. PubMed ID: 29020455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cystic fibrosis in an era of genomically guided therapy.
    Barrett PM; Alagely A; Topol EJ
    Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.